Synonym |
Thai / English name |
Part Used : ไม่ระบุActivity : CYP2C INHIBITIONSolvent/Active Compound : KaempferolType of experiment : in vitroType of animal : -Type of study : -N(Total) : -N(Treatment) : -Sex : -Age : -Route : -Dose/Conc.(herb) : 1-100 micromolarDuration : -Type of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : 1 millimolarResult : PositiveRemark : Kaempferol produced 73.1% and 52.5% CYP2C inhibition at 100 and 10 micromolar, respectively. However, no significant effect was observed in the presence of 1 micromolar of this compound.
Part Used : ใบActivity : DRUG INTERACTIONSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : -Result : PositiveRemark : - Tolbutamide 125 mg were orally administered to 10 male healthy volunteers before and after GBE intake, and received 75 g glucose after the dosing of tolbutamide. - The area under concentration vs. time curve (AUC0-alpha) for tolbutamide after GBE intake was slightly but significantly (16%) lower than that before GBE intake. Concomitantly, GBE tended to attenuate AUC0-2 of blood glucose-lowering effect of tolbutamide.Note : - Data incomplete
Part Used : ใบActivity : EFFECTS ON PHARMACOKINETICSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : -Result : PositiveRemark : - Tolbutamide 125 mg were orally administered to 10 male healthy volunteers before and after GBE intake, and received 75 g glucose after the dosing of tolbutamide. - The area under concentration vs. time curve (AUC0-alpha) for tolbutamide after GBE intake was slightly but significantly (16%) lower than that before GBE intake. Concomitantly, GBE tended to attenuate AUC0-2 of blood glucose-lowering effect of tolbutamide.Note : - Data incomplete
Part Used : ใบActivity : CYP2C9 INDUCTIONSolvent/Active Compound : Ginkgo biloba extraction (GBE)Type of experiment : humanType of animal : -Type of study : Open trialN(Total) : 10N(Treatment) : 10Sex : MaleAge : -Route : Oral administrationDose/Conc.(herb) : GBE intake 360 mg/dDuration : 28 daysType of interaction : PharmacokineticsInteraction with drug : TolbutamideDose/Conc.(drug) : -Result : PositiveRemark : - Tolbutamide 125 mg were orally administered to 10 male healthy volunteers before and after GBE intake, and received 75 g glucose after the dosing of tolbutamide. - The area under concentration vs. time curve (AUC0-alpha) for tolbutamide after GBE intake was slightly but significantly (16%) lower than that before GBE intake. Concomitantly, GBE tended to attenuate AUC0-2 of blood glucose-lowering effect of tolbutamide.Note : - Data incomplete